Preparation method of medicine for treating knee joint degenerative change
By combining plasma and metacellular PRP plasma with placental stem cells and using ultrasonic cell rupture technology to solve the problem of poor efficacy in knee injury treatment, cartilage repair and anti-inflammatory effects, and delaying the knee joint The necessity of replacement surgery and reduces the side effects of painkillers and improves the quality of life of patients.
Patent Information
- Application Number
- CN202411023938.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-29
- Publication Date
- 2024-11-08
AI Technical Summary
The existing knee injury treatment methods are not effective, especially the drug treatment effect is not good, and the recovery time after knee arthroplasty surgery is long, resulting in the limitation of the prognosis of knee injury and the lack of non-invasive and effective treatment methods.
By preparing a mixture of plasma and metacellular PRP concentrates and combined with placental stem cells, treated using ultrasonic cell breakage technology, a therapeutic drug injectable into the knee joint is formed to promote cartilage repair and anti-inflammatory.
This drug can effectively promote the repair of cartilage damage, has efficient immune regulation and anti-inflammatory effects, delay the necessity of knee arthroplasty, reduce the side effects of pain-relieving drugs, and improve the quality of life of patients.
Smart Images

Figure BDA0004968027960000041
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of knee joint treatment, and more specifically, to a method for preparing a medicine for treating knee joint degenerative lesions. Background Art
[0002] Arthritis caused by joint degeneration and injury is known as the "world's leading cause of disability, chronic disease". As one of the main bearers of daily activities, knee joints are more commonly damaged. The knee joint is mainly composed of three bones: femur, tibia and patella. Ligaments keep these three bones stable. The joint surface also has cartilage. Chondrocytes in the cartilage, the growth of chondrocytes, the survival of joint fluid and healthy joint fluid are very important to the entire knee joint. Problems in these parts may lead to the occurrence of knee arthritis.
[0003] At present, the treatments for knee injuries include heat therapy, ultrasound therapy, Western medicine analgesia, Chinese medicine external and internal administration, blocking injections, knee joint cavity injection of sodium hyaluronate, knee replacement, etc. However, the poor efficacy of drug treatment and the long recovery time after knee replacement surgery limit the prognosis of knee injuries. Therefore, it is urgent to find a non-invasive and effective treatment. Summary of the invention
[0004] The purpose of the present invention is to overcome the above-mentioned defects in the prior art and provide a method for preparing a drug for treating degenerative lesions of the knee joint.
[0005] To achieve the above object, the technical solution provided by the present invention is as follows: A method for preparing a drug for treating degenerative lesions of the knee joint, comprising the following steps:
[0006] (1) After disinfecting and wiping the blood collection tube containing qualified blood samples, transfer it to a clean workbench, then wipe the interface of the blood collection tube with a cotton ball and then pass it through a flame. Use hemostatic forceps to open the blood collection tube and mix the blood samples and divide them equally into two 50ml centrifuge tubes. The blood sample in each 50ml centrifuge tube should not exceed 30ml;
[0007] (2) Centrifuge two 50 ml centrifuge tubes with balanced blood samples at 200 g for 10 min, set the speed up gear to 2, and the speed down gear to 3. After centrifugation, the plasma is in the upper layer and the blood cells are in the lower layer. Then, use a 5 mL pipette to take the upper plasma from the two 50 ml centrifuge tubes and transfer them to two 15 ml centrifuge tubes. Add 10-30% of the plasma volume of the pro-cell PRP concentrate to each 15 ml centrifuge tube. After covering the lid, slowly invert each 15 ml centrifuge tube 10 times. Then, centrifuge the two 15 ml centrifuge tubes at 1000 g for 10 min, set the speed up gear to 4, and the speed down gear to 6.
[0008] (3) Discard the excess plasma in the two 15 ml centrifuge tubes after centrifugation, resuspend the remaining mixed solution in the two 15 ml centrifuge tubes with a 5 ml pipette, and dispense into two 5 ml cryotubes. Cover the cryotubes with caps and seal with sealing film;
[0009] (4) Transfer two 5 ml cryovials into a liquid nitrogen tank and freeze for 30 min. After freezing, thaw at room temperature and repeat freeze-thaw three times.
[0010] (5) After disinfection, transfer the two 5 ml cryotubes to a clean workbench, remove the sealing film, wipe the tube mouth with alcohol, and use a pipette to transfer the mixed solution in the two 5 ml cryotubes to two other new 50 ml centrifuge tubes. Insert the probe of the ultrasonic cell disruptor into the middle of the liquid surface of the two 50 ml centrifuge tubes, cool the two 50 ml centrifuge tubes with an ice-water mixture, and use the ultrasonic cell disruptor for 3 cycles;
[0011] (6) After the disruption is completed, use two 5 ml syringes to aspirate the filtered lysate mixture in two 50 ml centrifuge tubes respectively, remove the needles of the 5 ml syringes, install needle filters, and filter into two other new 5 ml cryotubes;
[0012] (7) 20 million units of placental stem cells are respectively mixed into the filtered lysed mixture in two 5 ml cryopreservation tubes to finally prepare a drug for treating degenerative lesions of the knee joint.
[0013] Preferably, the metacellular PRP concentrate is composed of the following raw materials in percentage by mass:
[0014] Dextran 85%~99%; calcium chloride 0.01%~5%; potassium chloride 0.01%~5%; sodium chloride 0.01%~5%; sodium lactate 0.01%~5%.
[0015] Preferably, in step (1), before the blood collection tube containing the qualified blood sample is disinfected and wiped, the blood sample report sheet needs to be checked.
[0016] Preferably, in step (1), the blood collection tube containing the qualified blood sample is disinfected and wiped with a dust-free cloth moistened with 75% alcohol.
[0017] Preferably, in step (1), a preset volume of blood sample is taken from a blood collection tube using a Pasteur pipette and transferred to an EP tube for a complete blood count.
[0018] Preferably, in step (2), the blood count results need to be registered on a computer when the two 50 ml centrifuge tubes are centrifuged.
[0019] Preferably, in step (3), after resuspending the remaining mixed solution in the two 15 ml centrifuge tubes with a 5 ml pipette, a preset volume of the mixed solution can be taken into another EP tube for counting with a hemocytometer.
[0020] Preferably, in step (5), the crushing is performed for 10 minutes, and the resting is performed for 5 minutes as one cycle.
[0021] Compared with the prior art, the present invention has the following beneficial effects:
[0022] The present invention can mix the plasma in the blood with the PRP concentrate of the prostate cells, and extract the concentrate therefrom for bio-cracking and then mix it with the placental stem cells to prepare a drug for treating degenerative lesions of the knee joint. The drug can be injected into the knee joint, which can not only promote the repair of cartilage damage, but also has efficient immunomodulatory and anti-inflammatory effects, can better stabilize osteoarthritis, relieve pain, thereby delaying the time for patients to undergo total knee replacement surgery, can effectively reduce the damage caused by side effects of long-term use of analgesics by arthritis patients, and improve the sense of happiness in daily life. DETAILED DESCRIPTION
[0023] In order to make the purpose, technical solution and advantages of the embodiments of the present invention clearer, the technical solution in the embodiments of the present invention will be described clearly and completely below. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0024] 1. Prepare instruments, reagents, and consumables
[0025] 1. Centrifuge, blood cell counter, electric pipette, liquid nitrogen tank, ultrasonic cell disruptor, water bath, refrigerator;
[0026] 2. Concentrate
[0027]
[0028] 3. 15mL centrifuge tube, 50mL centrifuge tube, 5mL pipette, 5ml freezing tube, EP tube, pipette, needle filter (0.22um), 5ml syringe, Pasteur pipette.
[0029] 2. The preparation method of the drug for treating knee joint degenerative lesions comprises the following steps:
[0030] (1) Blood sample preparation: Check the blood sample report, pass the qualified blood sample through the transfer window, disinfect and wipe the blood collection tube containing the qualified blood sample with a dust-free cloth moistened with 75% alcohol, and then transfer it to the clean workbench. Then, wipe the interface of the blood collection tube with a cotton ball and then pass it through fire. After opening the blood collection tube with hemostatic forceps, mix the blood sample and divide it equally into two 50ml centrifuge tubes. The blood sample in each 50ml centrifuge tube should not exceed 30ml. Use a Pasteur pipette to take a small amount of blood sample (e.g., 1ml) from the blood collection tube and transfer it to an EP tube for full blood count;
[0031] (2) Separation of plasma: centrifuge two 50 ml centrifuge tubes with balanced blood samples at 200 g for 10 min, set the speed up gear to 2, and the speed down gear to 3. During centrifugation, the blood count results need to be registered on the computer. After centrifugation, the plasma and blood cells are separated into layers, with the plasma in the upper layer and the blood cells in the lower layer. Then, use a 5 mL pipette to take the upper plasma from the two 50 ml centrifuge tubes and transfer them to two 15 ml centrifuge tubes. Add 10 to 30% (preferably 20%) of the plasma volume of the pro-cell PRP concentrate to each 15 ml centrifuge tube. After covering the lid, slowly invert each 15 ml centrifuge tube 10 times. Then, centrifuge the two 15 ml centrifuge tubes at 1000 g for 10 min, set the speed up gear to 4, and the speed down gear to 6.
[0032] (3) Counting and packaging: discard the excess plasma in the two 15 ml centrifuge tubes after centrifugation, resuspend the remaining mixed solution in the two 15 ml centrifuge tubes with a 5 ml pipette, and dispense into two 5 ml cryotubes. Cover the cryotubes with caps, seal them with sealing film, and take a small amount (e.g., 1 ml) of the mixed solution into another EP tube for counting with a hemocytometer;
[0033] (4) Freeze-thaw: transfer two 5 ml cryovials into a liquid nitrogen tank and freeze for 30 min. After freezing, thaw at room temperature and repeat freeze-thaw three times.
[0034] (5) Disruption: After disinfecting two 5 ml cryotubes, transfer them to a clean workbench, remove the sealing film, wipe the tube mouth with alcohol, and use a pipette to transfer the mixed solution in the two 5 ml cryotubes to two other new 50 ml centrifuge tubes. Insert the probe of the ultrasonic cell disruptor into the middle of the liquid surface of the two 50 ml centrifuge tubes, cool the two 50 ml centrifuge tubes with an ice-water mixture, and use the ultrasonic cell disruptor for 3 cycles;
[0035] In step (5), one cycle is to crush for 10 minutes and then stop for 5 minutes.
[0036] (6) Filtration: After the crushing is completed, use two 5 ml syringes to respectively aspirate the filtered lysate mixture in two 50 ml centrifuge tubes, remove the needles of the 5 ml syringes, install needle filters, and filter into two other new 5 ml cryotubes;
[0037] (7) Stem cell mixing: 20 million units of placental stem cells are mixed into the filtered lysed mixture in two 5 ml cryopreservation tubes respectively, and finally a drug for treating degenerative lesions of the knee joint is prepared.
[0038] Placental stem cells have the ability to self-differentiate. In the cartilage repair of knee osteoarthritis, they can migrate to the damaged soft tissue and then differentiate into chondrocytes to repair the defective cartilage.
[0039] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.
Claims
1. A method for preparing a drug for treating degenerative lesions of the knee joint, characterized in that: The following steps are involved: (1) After disinfecting and wiping the blood collection tube containing qualified blood samples, transfer it to a clean workbench, then wipe the interface of the blood collection tube with a cotton ball and then pass it through a flame. Use hemostatic forceps to open the blood collection tube and mix the blood samples and divide them equally into two 50ml centrifuge tubes. The blood sample in each 50ml centrifuge tube should not exceed 30ml; (2) Centrifuge two 50 ml centrifuge tubes with balanced blood samples at 200 g for 10 min, set the speed up gear to 2, and the speed down gear to 3. After centrifugation, the plasma is in the upper layer and the blood cells are in the lower layer. Then, use a 5 mL pipette to take the upper plasma from the two 50 ml centrifuge tubes and transfer them to two 15 ml centrifuge tubes. Add 10-30% of the plasma volume of the pro-cell PRP concentrate to each 15 ml centrifuge tube. After covering the lid, slowly invert each 15 ml centrifuge tube 10 times. Then, centrifuge the two 15 ml centrifuge tubes at 1000 g for 10 min, set the speed up gear to 4, and the speed down gear to 6. (3) Discard the excess plasma in the two 15 ml centrifuge tubes after centrifugation, resuspend the remaining mixed solution in the two 15 ml centrifuge tubes with a 5 ml pipette, and dispense into two 5 ml cryotubes. Cover the cryotubes with caps and seal with sealing film; (4) Transfer two 5 ml cryovials into a liquid nitrogen tank and freeze for 30 min. After freezing, thaw at room temperature and repeat freeze-thaw three times. (5) After disinfection, transfer the two 5 ml cryotubes to a clean workbench, remove the sealing film, wipe the tube mouth with alcohol, and use a pipette to transfer the mixed solution in the two 5 ml cryotubes to two other new 50 ml centrifuge tubes. Insert the probe of the ultrasonic cell disruptor into the middle of the liquid surface of the two 50 ml centrifuge tubes, cool the two 50 ml centrifuge tubes with an ice-water mixture, and use the ultrasonic cell disruptor for 3 cycles; (6) After the disruption is completed, use two 5 ml syringes to aspirate the filtered lysate mixture in two 50 ml centrifuge tubes respectively, remove the needles of the 5 ml syringes, install needle filters, and filter into two other new 5 ml cryotubes; (7) 20 million units of placental stem cells are respectively mixed into the filtered lysed mixture in two 5 ml cryopreservation tubes to finally prepare a drug for treating degenerative lesions of the knee joint.
2. The method for preparing a drug for treating knee joint degenerative lesions according to claim 1, characterized in that: The PRP concentrate is composed of the following raw materials in percentage by mass: Dextran 85% to 99%; Calcium chloride 0.01% to 5%; Potassium chloride 0.01%~5%; Sodium chloride 0.01%~5%; Sodium lactate 0.01%~5%.
3. The method for preparing a drug for treating knee joint degenerative lesions according to claim 1, characterized in that: In step (1), before the blood collection tube containing the qualified blood sample is disinfected and wiped, the blood sample report sheet needs to be checked.
4. The method for preparing a drug for treating knee joint degenerative lesions according to claim 1, characterized in that: In step (1), the blood collection tube containing the qualified blood sample is disinfected and wiped with a dust-free cloth moistened with 75% alcohol.
5. The method for preparing a drug for treating knee joint degenerative lesions according to claim 1, characterized in that: In step (1), a preset volume of blood sample is taken from a blood collection tube using a Pasteur pipette and transferred to an EP tube for complete blood count.
6. The method for preparing a drug for treating knee joint degenerative lesions according to claim 1, characterized in that: In step (2), the blood count results need to be registered on the computer when the two 50 ml centrifuge tubes are centrifuged.
7. The method for preparing a drug for treating knee joint degenerative lesions according to claim 1, characterized in that: In step (3), after resuspending the remaining mixed solution in the two 15 ml centrifuge tubes with a 5 ml pipette, a preset volume of the mixed solution can be taken into another EP tube for counting with a hemocytometer.
8. The method for preparing a drug for treating knee joint degenerative lesions according to claim 1, characterized in that: In step (5), one cycle is to crush for 10 minutes and then stop for 5 minutes.
